| Texto completo | |
| Autor(es): Mostrar menos - |
Marcos Pais
;
Luana Martinez
;
Octávio Ribeiro
;
Júlia Loureiro
;
Romel Fernandez
;
Leandro Valiengo
;
Paulo Canineu
;
Florindo Stella
;
Leda Talib
;
Marcia Radanovic
;
Orestes V. Forlenza
Número total de Autores: 11
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Revista Brasileira de Psiquiatria; n. ahead, p. -, 2020. |
| Resumo | |
The prevalence of Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the “amyloid cascade” and the “continuum of AD,” discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed. (AU) | |
| Processo FAPESP: | 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN) |
| Beneficiário: | Wagner Farid Gattaz |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |